Fig. 3
From: The potential of cystatin C as a predictive biomarker in pulmonary hypertension
Kaplan–Meier analysis for the probability of endpoint events. A Patients stratified by the cystatin C cut-off; B Patients stratified by the Swedish/COMPERA risk model; C Patients stratified by the combination of cystatin C and World Health Organization functional class. Presents the Kaplan–Meier analysis, which illustrates the probability of endpoint events stratified by cystatin C cut-off (1.0 mg/L), Swedish/COMPERA risk model and the combination of cystatin C and WHO-FC